Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.
Similar Posts
Decentralised Manufacture: Labelling
Guidance on labelling requirements pertinent to the type of medicinal product and its supply status, as defined in UK legislation.
Patient and family experiences inform antidepressant safety information review
An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients
Field Safety Notices: 22 to 26 September 2025
List of Field Safety Notices from 22 to 26 September 2025.
Guidance: Timelines for acceptance of CE marked medical devices in Great Britain (GB)
Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.
Decision: Advertising Investigations: May 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Research: Digital mental health technology: user and public perspectives on identifying and reporting harms
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.